Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levoketoconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 known ✓ | P05093 | 15/20 | 1.00 |
| ▸ | CYP11B1 known ✓ | P15538 | 14/20 | 1.00 |
| ▸ | CYP11B2 known ✓ | P19099 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 19/20 | 1.00 |
| ▸ | CYP21A2 | P08686 | 16/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 16/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | CYP27B1 | O15528 | 1/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levoketoconazole SCHEMBL29384825 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL13606596 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL13575830 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Ketoconazole SCHEMBL18258319 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Ketoconazole SCHEMBL8408 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL24312989 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL41473 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL8407 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL1517472 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL11213392 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3756665-B1 | INTERVAL THERAPY FOR THE TREATMENT OF EYE DISEASES | UNIV RAMOT (IL) | 2024-08-14 | — | — | EP | claimed |
| EP-3863634-B1 | LEVOKETOCONAZOLE FOR TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | STRONGBRIDGE DUBLIN LTD (IE) | 2026-04-08 | — | — | EP | disclosed |
| US-20260076981-A1 | HAIR REGROWTH TOPICAL COMPOSITION | SPEIER GARY J (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2025202885-A1 | ANTIMICROBIAL ACTIVES AND THEIR COMPOSITIONS THEREOF | S H KELKAR AND COMPANY LIMITED (IN) | 2025-10-02 | — | — | WO | disclosed |
| EP-4615469-A2 | COMPOSITIONS COMPRISING STABLE FREE AVAILABLE CHLORINE SPECIES AND PEROXIDES, METHODS OF MAKING AND USES THEREOF | Collidion, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-3534867-B1 | MEDICAL COMPOSITION CONTAINING GUANIDINYL-CONTAINING POLYMER(S) AND CARRAGEENANE(S) | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-3534866-B1 | METHOD OF DENTAL RETRACTION WITH COMPOSITION WITH GUANIDINYL-CONTAINING POLYMER | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2025038870-A1 | DOUBLE STRANDED RNA METHODS AND COMPOSITIONS FOR INSECTICIDE | RNAISSANCE AG LLC (US) | 2025-02-20 | — | — | WO | disclosed |
| US-12201632-B2 | Levoketoconazole for treatment of congenital adrenal hyperplasia and primary aldosteronism | STRONGBRIDGE DUBLIN LIMITED (IE) | 2025-01-21 | — | — | US | disclosed |
| EP-4488360-A1 | DEGRADATION OF FLUOR CONTAINING SUBSTANCES BY BIOCONVERSION | Universiteit Utrecht Holding B.V. (NL) | 2025-01-08 | — | — | EP | disclosed |
| US-11559671-B2 | Drug eluting balloon | ORBUSNEICH MEDICAL PTE. LTD. (SG) | 2023-01-24 | — | — | US | disclosed |
| EP-4118092-A1 | IMMUNOMODULATING O-HET-ARYL AZALIDES | Zoetis Services LLC (US) | 2023-01-18 | — | — | EP | disclosed |
| EP-2658527-B1 | NANOPARTICLE AND SURFACE-MODIFIED PARTICULATE COATINGS, COATED BALLOONS, AND METHODS THEREFORE | MICELL TECHNOLOGIES INC (US) | 2022-11-30 | — | — | EP | disclosed |
| US-11497834-B1 | Supercritical method of making a biocompatible composite implant | Bio Protectant Technologies, Inc. (US) | 2022-11-15 | — | — | US | disclosed |
| WO-2022228651-A1 | PYRUVATE ESTERS FOR THE TREATMENT OF VIRAL DISEASES | BIRKENMEIER GERD (DE) | 2022-11-03 | — | — | WO | disclosed |
| US-11426494-B2 | Stents having biodegradable layers | MT Acquisition Holdings LLC (US) | 2022-08-30 | — | — | US | disclosed |
| US-11382888-B2 | Combination of topical medications for the treatment of skin diseases and methods of use | AMERICAN UNIVERSITY OF BEIRUT (LB) | 2022-07-12 | — | — | US | disclosed |
| US-11369498-B2 | Stent and stent delivery system with improved deliverability | MT Acquisition Holdings LLC (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2022123395-A1 | DENTAL RETRACTION COMPOSITION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2022-06-16 | — | — | WO | disclosed |
| CN-114555654-A | Antimicrobial nano-worms | 波音公司 | 2022-05-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11382888-B2 | Combination of topical medications for the treatment of skin diseases and methods of use | ASAH2, TSLP, SLC5A6 | CYP17A1 199/4885CYP11B1 822/4885CYP11B2 457/4885 |
| US-20260076981-A1 | HAIR REGROWTH TOPICAL COMPOSITION | CYP2R1, CYP24A1, CYP17A1 | CYP17A1 3/4885CYP11B1 261/4885CYP11B2 285/4885 |
| US-12201632-B2 | Levoketoconazole for treatment of congenital adrenal hyperplasia and primary aldosteronism | HSD3B1, HSD3B2, HSD11B2 | CYP17A1 12/4885CYP11B1 27/4885CYP11B2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.